David F. Choy

TL;DR: Asthma can be divided into at least two distinct molecular phenotypes defined by degree of Th2 inflammation, and Th2 cytokines are likely to be a relevant therapeutic target in only a subset of patients with asthma.

TL;DR: The difference in exacerbation frequency between omalizumab and placebo was greatest in the three high-biomarker subgroups, probably associated with the greater risk for exacerbations in high subgroups.

TL;DR: Periostin is a systemic biomarker of airway eosinophilia in asthmatic patients and has potential utility in patient selection for emerging asthma therapeutics targeting T(H)2 inflammation.

TL;DR: It is demonstrated that asthma can be divided into three immunological clusters: TH2-high, TH17- high, and TH2/17- low, and the data suggest that combination therapies targeting both pathways may better treat asthmatic individuals.

TL;DR: In this article, the authors evaluated relationships between the bronchial microbiome and features of severe asthma using 16S ribosomal RNA-based methods and found that specific microbiota are associated with and may modulate inflammatory processes in patients with severe asthma and related phenotypes.